Actively Recruiting
Levothyroxine Supplementation for Heart Transplant Recipients
Led by University of California, San Francisco · Updated on 2025-05-01
97
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
CONDITIONS
Official Title
Levothyroxine Supplementation for Heart Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be listed for heart transplantation
- Age 18 years or older
- Ability to understand and willingness to sign a written informed consent document
You will not qualify if you...
- Patients with pre-existing thyroid conditions including hypothyroidism, hyperthyroidism, or thyroid cancer
- Patients with known allergy or intolerance to levothyroxine
- Patients who have participated in another investigational drug study within the past 30 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
S
Sarah Sullivan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here